ºñÀν¶¸° ´ç´¢º´ Ä¡·á ½ÃÀå, 2024-2028³â
ºñÀν¶¸° ´ç´¢º´ Ä¡·á ½ÃÀåÀº 2023-2028³â¿¡ 397¾ï 2,210¸¸ ´Þ·¯, ¿¹Ãø ±â°£ Áß CAGRÀº 12.17%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñÀν¶¸° ´ç´¢º´ Ä¡·á ½ÃÀåÀÇ ÀüüÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¡¤¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´Ù·é º¥´õ ºÐ¼® µîÀ» °ÔÀçÇϰí ÀÖ½À´Ï´Ù.
ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ°ú ÃËÁø¿äÀÎ, ½ÃÀå ȯ°æ Àüü¿¡ °üÇÑ ÃֽŠºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù. 2Çü ´ç´¢º´ ȯÀÚÀÇ Áõ°¡, 6-19¼¼¿Í 35-50¼¼ »çÀÌ¿¡¼ ´ç´¢º´ À¯º´·üÀÇ Áõ°¡, ÃÖ±Ù Á¦Ç° ½ÂÀÎ µîÀÌ ½ÃÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ |
±âÁسâ |
2024³â |
Á¾·á³â |
2028³â |
¿¹Ãø ±â°£ |
2024-2028³â |
¼ºÀå ¸ð¸àÅÒ |
°¡¼Ó |
Àü³â´ëºñ[2024³â] |
10.62% |
CAGR |
12.17% |
ÁõºÐ¾× |
397¾ï 2,210¸¸ ´Þ·¯ |
º» Á¶»ç¿¡¼´Â ÇâÈÄ ¼ö³â°£ ºñÀν¶¸° ´ç´¢º´ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÇ Çϳª·Î Ä¡·á¹ýÀÇ Çõ½ÅÀ» µé°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ º¥´õ°£ Àü·«Àû Á¦ÈÞ ¹× º´¿ë¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ½ÃÀåÀÇ Å« ¼ö¿ä·Î ¿¬°áµÉ °ÍÀ¸·Î »ý°¢µÇ°í ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå °³¿ä
Á¦2Àå ½ÃÀå ±¸µµ
- ½ÃÀå ¿¡ÄڽýºÅÛ
- ½ÃÀåÀÇ Æ¯Â¡
- ¹ë·ùüÀÎ ºÐ¼®
Á¦3Àå ½ÃÀå ±Ô¸ðÀÇ Æò°¡
- ½ÃÀåÀÇ Á¤ÀÇ
- ½ÃÀå ºÎ¹® ºÐ¼®
- ½ÃÀå ±Ô¸ð 2023³â
- ½ÃÀå Àü¸Á 2023-2028³â
Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû
- ¼¼°èÀÇ ºñÀν¶¸° ´ç´¢º´ Ä¡·á ½ÃÀå 2018-2022³â
- À¯Çüº° ºÎ¹® ºÐ¼® 2018-2022³â
- À¯Åë ä³Îº° ºÎ¹® ºÐ¼® 2018-2022³â
- Áö¿ªº° ºÎ¹® ºÐ¼® 2018-2022³â
- ±¹°¡º° ºÎ¹® ºÐ¼® 2018-2022³â
Á¦5Àå Five Forces ºÐ¼®
- Five Forces ¿ä¾à
- ¹ÙÀ̾îÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀïÀÇ À§Çù
- ½ÃÀå ÇöȲ
Á¦6Àå À¯Çüº° ½ÃÀå ¼¼ºÐÈ
- ½ÃÀå ¼¼ºÐÈ
- ºñ±³ : À¯Çüº°
- DPP4 ÀúÇØÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- SGLT2 ÀúÇØÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- ±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- À¯Çüº° ½ÃÀå ±âȸ
Á¦7Àå À¯Åë ä³Îº° ½ÃÀå ¼¼ºÐÈ
- ½ÃÀå ¼¼ºÐÈ
- ºñ±³ : À¯Åë ä³Îº°
- ¿ÀÇÁ¶óÀÎ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- ¿Â¶óÀÎ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- À¯Åë ä³Îº° ½ÃÀå ±âȸ
Á¦8Àå °í°´ »óȲ
Á¦9Àå Áö¿ªº° »óȲ
- Áö¿ªº° ¼¼ºÐÈ
- ºñ±³ : Áö¿ªº°
- ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- ¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- ±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- ¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- Áß±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- ¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- Àεµ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
- Áö¿ª »óȲº° ½ÃÀå ±âȸ
Á¦10Àå ÃËÁø¿äÀΡ¤°úÁ¦¡¤±âȸ¡¤¾ïÁ¦¿äÀÎ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
- ½ÃÀå ±âȸ¡¤¾ïÁ¦¿äÀÎ
Á¦11Àå °æÀï ±¸µµ
- °³¿ä
- °æÀï ±¸µµ
- È¥¶õ »óȲ
- ¾÷°è ¸®½ºÅ©
Á¦12Àå °æÀï ºÐ¼®
- ±â¾÷ °³¿ä
- ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×
- Abbott Laboratories
- AstraZeneca Plc
- Better Therapeutics Inc.
- Boehringer Ingelheim International GmbH
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck KGaA
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- The Cleveland Clinic Foundation
Á¦13Àå ºÎ·Ï
KSA
Non-insulin Diabetes Therapeutics Market 2024-2028
The non-insulin diabetes therapeutics market is forecasted to grow by USD 39722.1 mn during 2023-2028, accelerating at a CAGR of 12.17% during the forecast period. The report on the non-insulin diabetes therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing number of people with type 2 diabetes, growing prevalence of diabetes among people aged 6-19 and 35-50, and recent product approvals.
Market Scope |
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 10.62% |
CAGR | 12.17% |
Incremental Value | $39722.1 mn |
Technavio's non-insulin diabetes therapeutics market is segmented as below:
By Type
- DPP4 inhibitors
- GLP-1 receptor agonists
- SGLT2 inhibitors
- Others
By Distribution Channel
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the innovations in therapies as one of the prime reasons driving the non-insulin diabetes therapeutics market growth during the next few years. Also, strategic alliances between vendors and increasing demand for combination drugs will lead to sizable demand in the market.
The report on the non-insulin diabetes therapeutics market covers the following areas:
- Non-insulin diabetes therapeutics market sizing
- Non-insulin diabetes therapeutics market forecast
- Non-insulin diabetes therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-insulin diabetes therapeutics market vendors that include Abbott Laboratories, AstraZeneca Plc, Better Therapeutics Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and The Cleveland Clinic Foundation. Also, the non-insulin diabetes therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market By Geographical Landscape
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
- 2.2 Market characteristics
- Market characteristics analysis
- 2.3 Value chain analysis
3 Market Sizing
- 3.1 Market definition
- Offerings of companies included in the market definition
- 3.2 Market segment analysis
- 3.3 Market size 2023
- 3.4 Market outlook: Forecast for 2023-2028
- Chart on Global - Market size and forecast 2023-2028 ($ million)
- Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
- 4.1 Global Non-Insulin Diabetes Therapeutics Market 2018 - 2022
- Historic Market Size - Data Table on Global Non-Insulin Diabetes Therapeutics Market 2018 - 2022 ($ million)
- 4.2 Type segment analysis 2018 - 2022
- Historic Market Size - Type Segment 2018 - 2022 ($ million)
- 4.3 Distribution Channel segment analysis 2018 - 2022
- Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
- 4.4 Geography segment analysis 2018 - 2022
- Historic Market Size - Geography Segment 2018 - 2022 ($ million)
- 4.5 Country segment analysis 2018 - 2022
- Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Five forces analysis - Comparison between 2023 and 2028
- 5.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2023 and 2028
- 5.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2023 and 2028
- 5.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2023 and 2028
- 5.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2023 and 2028
- 5.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2023 and 2028
- 5.7 Market condition
- Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type
- 6.1 Market segments
- Chart on Type - Market share 2023-2028 (%)
- Data Table on Type - Market share 2023-2028 (%)
- 6.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
- 6.3 DPP4 inhibitors - Market size and forecast 2023-2028
- Chart on DPP4 inhibitors - Market size and forecast 2023-2028 ($ million)
- Data Table on DPP4 inhibitors - Market size and forecast 2023-2028 ($ million)
- Chart on DPP4 inhibitors - Year-over-year growth 2023-2028 (%)
- Data Table on DPP4 inhibitors - Year-over-year growth 2023-2028 (%)
- 6.4 GLP-1 receptor agonists - Market size and forecast 2023-2028
- Chart on GLP-1 receptor agonists - Market size and forecast 2023-2028 ($ million)
- Data Table on GLP-1 receptor agonists - Market size and forecast 2023-2028 ($ million)
- Chart on GLP-1 receptor agonists - Year-over-year growth 2023-2028 (%)
- Data Table on GLP-1 receptor agonists - Year-over-year growth 2023-2028 (%)
- 6.5 SGLT2 inhibitors - Market size and forecast 2023-2028
- Chart on SGLT2 inhibitors - Market size and forecast 2023-2028 ($ million)
- Data Table on SGLT2 inhibitors - Market size and forecast 2023-2028 ($ million)
- Chart on SGLT2 inhibitors - Year-over-year growth 2023-2028 (%)
- Data Table on SGLT2 inhibitors - Year-over-year growth 2023-2028 (%)
- 6.6 Others - Market size and forecast 2023-2028
- Chart on Others - Market size and forecast 2023-2028 ($ million)
- Data Table on Others - Market size and forecast 2023-2028 ($ million)
- Chart on Others - Year-over-year growth 2023-2028 (%)
- Data Table on Others - Year-over-year growth 2023-2028 (%)
- 6.7 Market opportunity by Type
- Market opportunity by Type ($ million)
- Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Distribution Channel
- 7.1 Market segments
- Chart on Distribution Channel - Market share 2023-2028 (%)
- Data Table on Distribution Channel - Market share 2023-2028 (%)
- 7.2 Comparison by Distribution Channel
- Chart on Comparison by Distribution Channel
- Data Table on Comparison by Distribution Channel
- 7.3 Offline - Market size and forecast 2023-2028
- Chart on Offline - Market size and forecast 2023-2028 ($ million)
- Data Table on Offline - Market size and forecast 2023-2028 ($ million)
- Chart on Offline - Year-over-year growth 2023-2028 (%)
- Data Table on Offline - Year-over-year growth 2023-2028 (%)
- 7.4 Online - Market size and forecast 2023-2028
- Chart on Online - Market size and forecast 2023-2028 ($ million)
- Data Table on Online - Market size and forecast 2023-2028 ($ million)
- Chart on Online - Year-over-year growth 2023-2028 (%)
- Data Table on Online - Year-over-year growth 2023-2028 (%)
- 7.5 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
- Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Chart on Market share By Geographical Landscape 2023-2028 (%)
- Data Table on Market share By Geographical Landscape 2023-2028 (%)
- 9.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2023-2028
- Chart on North America - Market size and forecast 2023-2028 ($ million)
- Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Chart on North America - Year-over-year growth 2023-2028 (%)
- Data Table on North America - Year-over-year growth 2023-2028 (%)
- 9.4 Europe - Market size and forecast 2023-2028
- Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Chart on Europe - Year-over-year growth 2023-2028 (%)
- Data Table on Europe - Year-over-year growth 2023-2028 (%)
- 9.5 Asia - Market size and forecast 2023-2028
- Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Chart on Asia - Year-over-year growth 2023-2028 (%)
- Data Table on Asia - Year-over-year growth 2023-2028 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- 9.7 US - Market size and forecast 2023-2028
- Chart on US - Market size and forecast 2023-2028 ($ million)
- Data Table on US - Market size and forecast 2023-2028 ($ million)
- Chart on US - Year-over-year growth 2023-2028 (%)
- Data Table on US - Year-over-year growth 2023-2028 (%)
- 9.8 Germany - Market size and forecast 2023-2028
- Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Chart on Germany - Year-over-year growth 2023-2028 (%)
- Data Table on Germany - Year-over-year growth 2023-2028 (%)
- 9.9 China - Market size and forecast 2023-2028
- Chart on China - Market size and forecast 2023-2028 ($ million)
- Data Table on China - Market size and forecast 2023-2028 ($ million)
- Chart on China - Year-over-year growth 2023-2028 (%)
- Data Table on China - Year-over-year growth 2023-2028 (%)
- 9.10 UK - Market size and forecast 2023-2028
- Chart on UK - Market size and forecast 2023-2028 ($ million)
- Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Chart on UK - Year-over-year growth 2023-2028 (%)
- Data Table on UK - Year-over-year growth 2023-2028 (%)
- 9.11 India - Market size and forecast 2023-2028
- Chart on India - Market size and forecast 2023-2028 ($ million)
- Data Table on India - Market size and forecast 2023-2028 ($ million)
- Chart on India - Year-over-year growth 2023-2028 (%)
- Data Table on India - Year-over-year growth 2023-2028 (%)
- 9.12 Market opportunity By Geographical Landscape
- Market opportunity By Geographical Landscape ($ million)
- Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Opportunity/Restraints
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2023 and 2028
- 10.4 Market opportunities/restraints
11 Competitive Landscape
- 11.1 Overview
- 11.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 11.3 Landscape disruption
- Overview on factors of disruption
- 11.4 Industry risks
- Impact of key risks on business
12 Competitive Analysis
- 12.1 Companies profiled
- 12.2 Market positioning of companies
- Matrix on companies position and classification
- 12.3 Abbott Laboratories
- Abbott Laboratories - Overview
- Abbott Laboratories - Business segments
- Abbott Laboratories - Key news
- Abbott Laboratories - Key offerings
- Abbott Laboratories - Segment focus
- 12.4 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- 12.5 Better Therapeutics Inc.
- Better Therapeutics Inc. - Overview
- Better Therapeutics Inc. - Product / Service
- Better Therapeutics Inc. - Key news
- Better Therapeutics Inc. - Key offerings
- 12.6 Boehringer Ingelheim International GmbH
- Boehringer Ingelheim International GmbH - Overview
- Boehringer Ingelheim International GmbH - Product / Service
- Boehringer Ingelheim International GmbH - Key news
- Boehringer Ingelheim International GmbH - Key offerings
- 12.7 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key news
- Eli Lilly and Co. - Key offerings
- 12.8 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- 12.9 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- 12.10 Johnson and Johnson Services Inc.
- Johnson and Johnson Services Inc. - Overview
- Johnson and Johnson Services Inc. - Business segments
- Johnson and Johnson Services Inc. - Key news
- Johnson and Johnson Services Inc. - Key offerings
- Johnson and Johnson Services Inc. - Segment focus
- 12.11 Merck KGaA
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key news
- Merck KGaA - Key offerings
- Merck KGaA - Segment focus
- 12.12 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- 12.13 Novo Nordisk AS
- Novo Nordisk AS - Overview
- Novo Nordisk AS - Business segments
- Novo Nordisk AS - Key news
- Novo Nordisk AS - Key offerings
- Novo Nordisk AS - Segment focus
- 12.14 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- 12.15 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- 12.16 Takeda Pharmaceutical Co. Ltd.
- Takeda Pharmaceutical Co. Ltd. - Overview
- Takeda Pharmaceutical Co. Ltd. - Product / Service
- Takeda Pharmaceutical Co. Ltd. - Key news
- Takeda Pharmaceutical Co. Ltd. - Key offerings
- 12.17 The Cleveland Clinic Foundation
- The Cleveland Clinic Foundation - Overview
- The Cleveland Clinic Foundation - Product / Service
- The Cleveland Clinic Foundation - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 13.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 13.4 Research methodology
- 13.5 Data procurement
- 13.6 Data validation
- 13.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 13.8 Data synthesis
- 13.9 360 degree market analysis
- 360 degree market analysis
- 13.10 List of abbreviations